USFDA completes inspection at Laurus Labs’ Visakhapatnam facility

09 Nov 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Laurus Labs’ FDF & API Integrated Facility, Unit 2, at Visakhapatnam. The inspection was carried out from November 04 - 08, 2019.

The company has been issued with two observations which are procedural in nature. This is a product pre-approval audit by USFDA.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1012.65 -5.55 (-0.55%)
04-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1818.60
Dr. Reddys Lab 1277.00
Cipla 1521.20
Zydus Lifesciences 935.20
Lupin 2091.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×